肝疾患治療薬の世界市場レポート 2025年

肝疾患治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で207億8,000万米ドルに成長します。予測期間の成長は、精密医療へのアプローチ、RNA治療薬の革新、線維症治療への注力、患者擁護・支援団体、肝炎ワクチンの開発、希少疾病用医薬品への規制支援などに起因すると考えられます。予測期間における主な動向は、C型肝炎治療の進歩、肝線維症に対する新規治療法の出現、免疫療法の探求、遠隔医療と遠隔モニタリング、栄養介入への注力などです。

肝疾患の有病率の増加は、今後数年間における肝疾患治療薬市場の成長を促進すると予想されます。肝疾患には肝臓に影響を及ぼすあらゆる疾患が含まれ、肝疾患治療薬はこれらの疾患に対処するための様々な治療オプションを提供します。例えば、英国の政府部門であるOffice for Health Improvement and Disparitiesの報告によると、2022年、イングランドの75歳未満の肝臓疾患による死亡率は人口10万人当たり21.4人に達しました。注目すべきは、男性の早期死亡が6,664人であるのに対し、女性は3,929人であることです。このように、肝疾患の罹患率の上昇は、肝疾患治療薬市場の成長を促進する重要な要因です。

高齢者人口の増加は、今後数年間における肝疾患治療薬市場の成長を促進すると予想されます。高齢者とは、一定の年齢に達した個人を指し、一般的には定年退職や人生の後期を意味します。肝疾患治療薬は、高齢者の肝臓に関連する健康問題に対処するために使用され、肝疾患を持つ高齢者の生活の質や全体的な健康を改善し、肝臓の健康を効果的に管理するために役立ちます。例えば、ケニアを拠点とする非営利団体Population Reference Bureauの報告書によると、65歳以上のアメリカ人人口は2022年の5,800万人から2050年には8,200万人に増加し、47％増になると予測されています。同期間中、この年齢層が全人口に占める割合は17％から23％に増加すると予想されています。したがって、高齢者人口の増加が、肝疾患治療薬市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肝疾患治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肝疾患治療薬市場：成長率分析
• 世界の肝疾患治療薬市場の実績：規模と成長、2019～2024年
• 世界の肝疾患治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の肝疾患治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肝疾患治療薬市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肝炎
• 非アルコール性脂肪肝
• アルコール性肝疾患
• 肝臓がん
• 世界の肝疾患治療薬市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗ウィルス薬
• ワクチン
• 化学療法
• 免疫抑制剤
• コルチコステロイド
• 世界の肝疾患治療薬市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 外来手術センター
• その他
• 世界の肝疾患治療薬市場：肝炎のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• A型肝炎
• B型肝炎
• C型肝炎
• D型肝炎
• 世界の肝疾患治療薬市場：非アルコール性脂肪肝（NAFLD）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 非アルコール性脂肪肝炎（NASH）
• 単純脂肪肝
• 世界の肝疾患治療薬市場：アルコール性肝疾患のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルコール性肝炎
• アルコール性肝硬変
• 世界の肝疾患治療薬市場：肝臓がんのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肝細胞がん（HCC）
• 胆管がん

第7章 地域別・国別分析

• 世界の肝疾患治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の肝疾患治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肝疾患治療薬市場：競合情勢
• 肝疾患治療薬市場：企業プロファイル
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline PLC
• Abbott Laboratories Inc.
• Pfizer Inc.
• Sanofi SA
• Johnson & Johnson Services Inc.
• Bayer AG
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals
• Watson Pharmaceuticals Inc.
• AstraZeneca PLC
• Gilead Sciences Inc.
• Endo International PLC
• Alnylam Pharmaceuticals Inc.
• Provectus Biopharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肝疾患治療薬市場2029年：新たな機会を提供する国
• 肝疾患治療薬市場2029年：新たな機会を提供するセグメント
• 肝疾患治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Liver disease therapeutics involve the treatment of various liver conditions, including those caused by viruses such as hepatitis A, B, and C. These therapies are crucial for improving the quality of life for individuals affected by liver diseases and for reducing the overall burden of liver disease on healthcare systems.

The primary disease classifications within liver disease therapeutics include hepatitis, non-alcoholic fatty liver disease, alcohol-induced conditions, and liver cancer. Hepatitis denotes liver inflammation caused by infectious viruses or noninfectious agents, leading to diverse health complications, some of which can be life-threatening. Treatment modalities encompass antiviral medications, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users of these therapeutics span hospitals, ambulatory surgery centers, and other sectors.

The liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.

The increasing prevalence of liver diseases is anticipated to drive the growth of the liver disease therapeutics market in the coming years. Liver disease encompasses any condition that affects the liver, and liver disease therapeutics provide various treatment options to address these conditions. For example, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that in 2022, the mortality rate from liver disease for individuals under 75 in England reached 21.4 per 100,000 population. Notably, there were 6,664 premature deaths among males compared to 3,929 among females. Thus, the rising incidence of liver diseases is a significant factor propelling the growth of the liver disease therapeutics market.

The expanding geriatric population is expected to drive the growth of the low-density polyethylene (LDPE) market in the coming years. The geriatric population refers to older individuals or senior citizens who have reached or surpassed a certain age, typically associated with retirement and the later stages of life. LDPE is increasingly utilized in the pharmaceutical industry to package liver disease therapeutics, which address liver-related health issues and improve the quality of life for elderly individuals. For instance, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the population of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During the same period, this age group's share of the overall population is expected to grow from 17% to 23%. Therefore, the expanding pharmaceutical industry, catering to the needs of the aging population, is contributing to the growth of the low-density polyethylene market.

Strategic partnerships represent a prominent trend in the liver disease therapeutics market. Leading companies within this sector are engaging in collaborations to fortify their positions. For instance, in January 2022, Aligos Therapeutics Inc., a US-based biopharmaceutical company, partnered with Merck & Co. to develop oligonucleotide therapies for non-alcoholic steatohepatitis. Similarly, in January 2021, Novartis collaborated with Alnylam to develop liver-targeted therapies as potential alternatives to transplantation for patients experiencing liver failure.

Prominent players in the liver disease therapeutics market prioritize innovative technologies, notably artificial intelligence (AI), to enhance patient care. AI applications in liver disease therapeutics involve sophisticated computational algorithms and machine learning techniques to analyze medical data, facilitating early detection, precise diagnosis, and personalized treatment strategies for liver diseases. For example, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT in February 2023. hepatoSIGHT, an AI-powered tool, predicts liver fibrosis in chronic liver disease patients, aiding case-finding and cohort mapping. It offers comprehensive data analysis, machine learning algorithms, real-time risk stratification, and user-friendly interfaces for efficient patient identification within seconds.

In September 2022, GENFIT, a biopharmaceutical company headquartered in France, completed the acquisition of Versantis for an undisclosed sum. This strategic acquisition integrates Versantis' specialized expertise in liver disease therapeutics with GENFIT's extensive knowledge in executing intricate development programs focused on liver diseases. This collaboration serves to reinforce and expedite research and development efforts, substantially broadening GENFIT's pipeline in this field. Versantis, based in Switzerland, specializes in therapeutic solutions for liver diseases.

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Hepatitis; Non-Alcoholic Fatty Liver Disease; Alcohol-Induced; Liver Cancer
• 2) By Treatment: Antiviral; Vaccines; Chemotherapy; Immunosuppressive Agents; Corticosteroids
• 3) By End User: Hospitals; Ambulatory Surgery Centers; Other End Users
• Subsegments:
• 1) By Hepatitis: Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D
• 2) By Non-Alcoholic Fatty Liver Disease (NAFLD): Non-Alcoholic Steatohepatitis (NASH); Simple Fatty Liver
• 3) By Alcohol-Induced Liver Disease: Alcoholic Hepatitis; Alcoholic Cirrhosis
• 4) By Liver Cancer: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma
• Companies Mentioned: Astellas Pharma Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liver Diseases Therapeutics Market Characteristics

3. Liver Diseases Therapeutics Market Trends And Strategies

4. Liver Diseases Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liver Diseases Therapeutics Market Growth Rate Analysis
• 5.4. Global Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liver Diseases Therapeutics Total Addressable Market (TAM)

6. Liver Diseases Therapeutics Market Segmentation

• 6.1. Global Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer
• 6.2. Global Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids
• 6.3. Global Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgery Centers
• Other End Users
• 6.4. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Hepatitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Hepatitis D
• 6.5. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Non-Alcoholic Fatty Liver Disease (NAFLD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Alcoholic Steatohepatitis (NASH)
• Simple Fatty Liver
• 6.6. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Alcohol-Induced Liver Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alcoholic Hepatitis
• Alcoholic Cirrhosis
• 6.7. Global Liver Diseases Therapeutics Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocellular Carcinoma (HCC)
• Cholangiocarcinoma

7. Liver Diseases Therapeutics Market Regional And Country Analysis

• 7.1. Global Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liver Diseases Therapeutics Market

• 8.1. Asia-Pacific Liver Diseases Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liver Diseases Therapeutics Market

• 9.1. China Liver Diseases Therapeutics Market Overview
• 9.2. China Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liver Diseases Therapeutics Market

• 10.1. India Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liver Diseases Therapeutics Market

• 11.1. Japan Liver Diseases Therapeutics Market Overview
• 11.2. Japan Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liver Diseases Therapeutics Market

• 12.1. Australia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liver Diseases Therapeutics Market

• 13.1. Indonesia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liver Diseases Therapeutics Market

• 14.1. South Korea Liver Diseases Therapeutics Market Overview
• 14.2. South Korea Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liver Diseases Therapeutics Market

• 15.1. Western Europe Liver Diseases Therapeutics Market Overview
• 15.2. Western Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liver Diseases Therapeutics Market

• 16.1. UK Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liver Diseases Therapeutics Market

• 17.1. Germany Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liver Diseases Therapeutics Market

• 18.1. France Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liver Diseases Therapeutics Market

• 19.1. Italy Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liver Diseases Therapeutics Market

• 20.1. Spain Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liver Diseases Therapeutics Market

• 21.1. Eastern Europe Liver Diseases Therapeutics Market Overview
• 21.2. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liver Diseases Therapeutics Market

• 22.1. Russia Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liver Diseases Therapeutics Market

• 23.1. North America Liver Diseases Therapeutics Market Overview
• 23.2. North America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liver Diseases Therapeutics Market

• 24.1. USA Liver Diseases Therapeutics Market Overview
• 24.2. USA Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liver Diseases Therapeutics Market

• 25.1. Canada Liver Diseases Therapeutics Market Overview
• 25.2. Canada Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liver Diseases Therapeutics Market

• 26.1. South America Liver Diseases Therapeutics Market Overview
• 26.2. South America Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liver Diseases Therapeutics Market

• 27.1. Brazil Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liver Diseases Therapeutics Market

• 28.1. Middle East Liver Diseases Therapeutics Market Overview
• 28.2. Middle East Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liver Diseases Therapeutics Market

• 29.1. Africa Liver Diseases Therapeutics Market Overview
• 29.2. Africa Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liver Diseases Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liver Diseases Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Liver Diseases Therapeutics Market Competitive Landscape
• 30.2. Liver Diseases Therapeutics Market Company Profiles
  • 30.2.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Liver Diseases Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Abbott Laboratories Inc.
• 31.3. Pfizer Inc.
• 31.4. Sanofi SA
• 31.5. Johnson & Johnson Services Inc.
• 31.6. Bayer AG
• 31.7. AbbVie Inc.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Valeant Pharmaceuticals
• 31.10. Watson Pharmaceuticals Inc.
• 31.11. AstraZeneca PLC
• 31.12. Gilead Sciences Inc.
• 31.13. Endo International PLC
• 31.14. Alnylam Pharmaceuticals Inc.
• 31.15. Provectus Biopharmaceuticals Inc.

32. Global Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liver Diseases Therapeutics Market

34. Recent Developments In The Liver Diseases Therapeutics Market

35. Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liver Diseases Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer